Comparison · NCT00823797-60725d5b
Treatment (Bendamustine Hydrochloride) for Glioblastoma vs Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma: PFS-6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment (Bendamustine Hydrochloride) for Glioblastoma vs Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma: PFS-6. Trial comparisons, record NCT00823797-60725d5b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00823797-60725d5b
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0625 | 0.0111 | 0.283 | wilson | |
| Risk in group 2 | 0.276 | 0.147 | 0.457 | wilson | |
| Risk difference, group 1 minus group 2 | -0.213 | -0.402 | 0.0423 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.227 | 0.0311 | 1.65 | log | |
| Odds ratio, group 1 over group 2 | 0.175 | 0.0197 | 1.55 | log | |
| Number needed to treat, for one fewer participant with the outcome on Treatment (Bendamustine Hydrochloride) for Glioblastoma than on Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma | 4.69 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment (Bendamustine Hydrochloride) for Glioblastoma | Glioblastoma Arm~Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. | 1 | 16 | OG000 |
| Group 2 | Treatment (Bendamustine Hydrochloride) for Anaplastic Glioma | Anaplastic Glioma Arm~Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. | 8 | 29 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- PFS-6
- Description
Defined as the proportion of patients who remain alive and free of any disease progression at 6 months. PFS over time will be estimated using the Kaplan-Meier method with standard errors estimated using Greenwood's formula.
- Time frame
- At 6 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
- NCT number
- NCT00823797
- Phases
- PHASE2
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Interventions
- Bendamustine Hydrochloride, Quality-of-Life Assessment
- Lead sponsor
- University of Washington
- Results first posted
- 2017-05-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00823797?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00823797-60725d5b